Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Cardiotoxicity 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma 3Sarcoma 2Leukemia 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pleuropulmonary blastoma 1PRETEXT I Hepatoblastoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Lymphoma, Large B-Cell, Diffuse 1Localized Extraskeletal Ewing Sarcoma 1Leukemia, Myeloid, Acute 1Leukemia, Biphenotypic, Acute 1Inflammatory Breast Neoplasms 1Heart Failure 1Ganglioneuroblastoma 1Drug-Related Side Effects and Adverse Reactions 1Dendritic Cell Sarcoma, Interdigitating 1Burkitt Lymphoma 1Breast Neoplasms 1

Interventions

temsirolimus 1dehydroftorafur 1Vincristine 1Sirolimus 1Razoxane 1Platinum 1Liver Transplantation 1Irinotecan 1Fluorouracil 1Doxorubicin 1Dexrazoxane 1Cisplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × PRETEXT I Hepatoblastoma × Dexrazoxane × Clear all
NCT00980460 2026-05-04

Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
236 enrolled 18 charts
Gastrointestinal

PRETEXT I Hepatoblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡